RE: Inan14 Mar 2020 13:29
so Tf from your point of view forget the vaccine for the moment let the industry see if they can create one that works first
but the key at the moment is to find antivirals that can limit the virus ability to kill, and that is also able to stop total organ failure , because this would mitigate the virus impact and instantly take away the virus ability to over power the NHS
because that could be a problem for years to come if the "new Virus" is here to stay with yearly mutations
so products like Tamiflu etc .. need to be able to engage this cronovirus .. and limit its impact
the Flu kills far more people every year ......... yet its not seen as so dangerous ? perception
Findings
EMR-contributing countries represented 57% of the global population. The estimated mean annual influenza-associated respiratory EMR ranged from 0·1 to 6·4 per 100?000 individuals for people younger than 65 years, 2·9 to 44·0 per 100?000 individuals for people aged between 65 and 74 years, and 17·9 to 223·5 per 100?000 for people older than 75 years. We estimated that 291?243–645?832 seasonal influenza-associated respiratory deaths (4·0–8·8 per 100?000 individuals) occur annually. The highest mortality rates were estimated in sub-Saharan Africa (2·8–16·5 per 100?000 individuals), southeast Asia (3·5–9·2 per 100?000 individuals), and among people aged 75 years or older (51·3–99·4 per 100?000 individuals). For 92 countries, we estimated that among children younger than 5 years, 9243–105?690 influenza-associated respiratory deaths occur annually.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)33293-2/fulltext
Sign In
Follow the stocks
